S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
NPCE · Neuropace, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
$13.04
-0.46
(-3.41%)
● At close: October 21 at 4:00:00 PM EDT
$13.05
+0.00
(+0.00%)
After-Hours:
4:01:38 PM EDT
DAY'S RANGE
$13.04
$13.04
$13.35
52-WEEK RANGE
$13.04
$9.22
$19.60
What's happening
- NPCE is down 3.41% today, trading at $13.04. — Live quote
- Volume today (3,645) is well below its 3-month average of 168,840. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.18 actual vs. $-0.21 estimated (+14.6%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 11
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (16 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
NPCE
-12.50%
vs S&P 500
-25.28%
1-YEAR RETURN
NPCE
+25.79%
vs S&P 500
+11.23%
6-MONTH RETURN
NPCE
-12.73%
3-MONTH RETURN
NPCE
-12.61%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.18
Est. $-0.21
BEAT +14.6%
2026-04-26 (Q1 2026)
$-0.20
Est. $-0.23
BEAT +12.4%
2026-01-26 (Q4 2025)
$-0.08
Est. $-0.15
BEAT +48.2%
2025-10-26 (Q3 2025)
$-0.11
Est. $-0.20
BEAT +45.1%
Valuation Measures & Ratios
Enterprise Value4$510.2M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)4.69
Price / Book745.59
EV4 / Revenue5.16
EV4 / EBITDA—
Profit Margin-19.34%
Operating Margin-15.26%
Return on Equity (ROE8)-119.68%
Return on Assets (ROA9)-18.71%
Avg Volume (3M)168,840
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $547.7M | $439.5M | $327.7M | $370.2M | $386.6M |
| P/E | -21.88 | -17.28 | -13.55 | -13.12 | -13.57 |
| Price/Sales | 5.97 | 4.81 | 3.62 | 4.50 | 4.77 |
| Price/Book | 46.09 | 30.40 | 17.69 | 19.04 | 15.93 |
| EV/Revenue | 6.48 | 5.29 | 4.04 | 4.93 | 5.18 |
| ROE | -210.69% | -175.90% | -130.62% | -145.11% | -117.35% |
| ROA | -25.81% | -25.71% | -22.55% | -26.58% | -25.84% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short903,626
Change from Prior Settlement-5.50%
% of Float—
Days to Cover (Short Ratio)6.18
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +25.8%. Finnhub market metrics ↗
- Latest SEC filing is Form 4, filed 2026-09-25; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Revenue growth is -3.0% on the provider's reported measure. Finnhub fundamentals ↗
- Net profit margin is -19.3%. Finnhub fundamentals ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on NPCE
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.8M | $22.1M | $27.4M | $19.5M | $22.5M | $21.1M | $19.3M | $18.1M |
| Gross profit | $18.9M | $18.0M | $21.2M | $16.2M | $17.3M | $15.4M | $14.1M | $13.3M |
| Operating income | -$5.1M | -$5.6M | -$2.6M | -$8.2M | -$5.1M | -$4.2M | -$6.2M | -$7.5M |
| Net income | -$6.2M | -$6.7M | -$3.5M | -$8.7M | -$6.6M | -$5.5M | -$7.5M | -$8.9M |
| EPS (diluted) | $-0.18 | $-0.20 | $-0.11 | $-0.26 | $-0.21 | $-0.19 | $-0.26 | $-0.32 |
| EPS (basic) | $-0.18 | $-0.20 | $-0.11 | $-0.26 | $-0.21 | $-0.19 | $-0.26 | $-0.32 |
| Operating margin | -$23 | -$25 | -$10 | -$42 | -$23 | -$20 | -$32 | -$42 |
| Net margin | -$27 | -$30 | -$13 | -$44 | -$29 | -$26 | -$39 | -$49 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $97.0M | $98.9M | $105.6M | $107.3M | $106.1M | $110.2M | $94.6M | $96.3M |
| Total liabilities | $85.1M | $84.4M | $86.5M | $88.7M | $86.7M | $85.9M | $86.6M | $86.5M |
| Stockholders' equity | $11.9M | $14.5M | $19.0M | $18.5M | $19.4M | $24.3M | $8.0M | $9.8M |
| Total current assets | $86.2M | $87.0M | $94.1M | $95.3M | $93.7M | $97.5M | $81.3M | $82.6M |
| Total current liabilities | $17.4M | $16.2M | $17.8M | $19.6M | $17.1M | $14.7M | $15.2M | $14.8M |
| Cash & equivalents | $12.5M | $14.8M | $21.7M | $20.6M | $22.9M | $27.0M | $13.4M | $15.4M |
| Marketable securities (current) | $39.2M | $39.2M | $39.4M | $39.4M | $39.3M | $39.2M | $39.3M | $41.4M |
| Accounts receivable | $14.9M | $14.8M | $12.9M | $14.9M | $13.6M | $15.4M | $12.9M | $11.6M |
| Inventory | $18.1M | $16.7M | $14.9M | $18.1M | $16.3M | $13.6M | $13.4M | $12.1M |
| Property, plant & equipment | $1.2M | $1.3M | $1.1M | $1.1M | $1.2M | $1.2M | $1.1M | $1.0M |
| Other non-current assets | $98.0K | $106.0K | $113.0K | $120.0K | $87.0K | $15.0K | $15.0K | $15.0K |
| Accounts payable | $4.2M | $4.5M | $1.8M | $4.6M | $4.7M | $4.0M | $3.0M | $2.2M |
| Accrued liabilities | $10.8M | $9.3M | $13.2M | $12.3M | $9.7M | $8.1M | $9.8M | $10.1M |
| Deferred revenue (current) | $123.0K | $126.0K | $141.0K | $649.0K | $696.0K | $680.0K | $555.0K | $749.0K |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | $59.0M | $59.0M | $58.9M | $58.7M | $58.6M | $59.8M | $59.5M | $59.3M |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $34.0K | $34.0K | $34.0K | $33.0K | $33.0K | $33.0K | $30.0K | $30.0K |
| Retained earnings | -$565.3M | -$559.1M | -$552.4M | -$549.7M | -$546.2M | -$537.5M | -$531.0M | -$525.7M |
| Accumulated other comprehensive income (loss) | — | — | — | — | — | — | — | — |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.9M | -$5.9M | $506.0K | -$1.9M | -$2.1M | -$7.5M | -$4.8M | -$1.7M |
| Investing cash flow | -$125.0K | -$117.0K | -$97.0K | -$30.0K | -$168.0K | -$37.0K | $2.0M | $1.4M |
| Financing cash flow | $1.2M | -$166.0K | $635.0K | -$235.0K | -$1.9M | $21.1M | $848.0K | $2.9M |
| Free cash flow | -$4.0M | -$6.0M | $409.0K | -$2.0M | -$2.3M | -$7.5M | -$4.8M | -$1.8M |
| Capital expenditures | $125.0K | $117.0K | $97.0K | $30.0K | $168.0K | $37.0K | $39.0K | $100.0K |
| Share-based compensation | $2.3M | $2.3M | $2.6M | $2.6M | $3.2M | $2.6M | $2.6M | $2.6M |
| Change in accounts receivable | $141.0K | $108.0K | -$257.0K | $1.4M | -$1.9M | $2.6M | $1.3M | $318.0K |
| Change in inventory | $1.5M | -$125.0K | -$1.2M | $1.8M | $2.8M | $243.0K | $1.4M | $828.0K |
| Change in accounts payable | -$212.0K | $2.2M | -$2.4M | -$48.0K | $737.0K | $966.0K | $773.0K | -$130.0K |
| Purchases of investments | — | — | — | — | — | — | — | — |
| Sales/maturities of investments | — | — | — | — | — | — | — | — |
| Share repurchases | $0 | $0 | $0 | $0 | $0 | $49.5M | $0 | $0 |
| Tax withholding on stock comp | $51.0K | $176.0K | $88.0K | $53.0K | $174.0K | $228.0K | $92.0K | $68.0K |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $100.0M | $79.9M | $65.4M | $45.5M | $45.2M |
| Gross profit | $77.2M | $59.1M | $48.1M | $32.5M | $33.4M |
| Operating income | -$16.3M | -$21.7M | -$27.2M | -$40.8M | -$23.7M |
| Net income | -$21.5M | -$27.1M | -$33.0M | -$47.1M | -$36.1M |
| EPS (diluted) | $-0.66 | $-0.93 | $-1.27 | $-1.91 | $-2.17 |
| EPS (basic) | $-0.66 | $-0.93 | $-1.27 | $-1.91 | $-2.17 |
| Operating margin | -$16 | -$27 | -$42 | -$90 | -$53 |
| Net margin | -$21 | -$34 | -$50 | -$103 | -$80 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $105.6M | $94.6M | $107.7M | $114.1M | $133.6M |
| Total liabilities | $86.5M | $86.6M | $87.0M | $79.3M | $60.1M |
| Stockholders' equity | $19.0M | $8.0M | $20.7M | $34.8M | $73.5M |
| Total current assets | $94.1M | $81.3M | $92.7M | $97.7M | $132.8M |
| Total current liabilities | $17.8M | $15.2M | $16.2M | $11.0M | $9.3M |
| Cash & equivalents | $21.7M | $13.4M | $18.1M | $6.6M | $19.2M |
| Marketable securities (current) | $39.4M | $39.3M | $48.4M | $70.8M | $96.4M |
| Accounts receivable | $14.7M | $12.9M | $12.3M | $7.5M | $7.1M |
| Inventory | $16.9M | $13.4M | $11.2M | $9.7M | $7.8M |
| Property, plant & equipment | $1.1M | $1.1M | $1.0M | $1.1M | $603.0K |
| Other non-current assets | $113.0K | $15.0K | $15.0K | $21.0K | $21.0K |
| Accounts payable | $2.2M | $3.0M | $2.3M | $2.1M | $1.4M |
| Accrued liabilities | $13.3M | $9.8M | $11.2M | $7.4M | $7.9M |
| Deferred revenue (current) | $141.0K | $555.0K | $1.1M | $0 | — |
| Short-term debt | — | — | — | — | $0 |
| Long-term debt | $58.9M | $59.5M | $57.0M | $52.9M | $49.8M |
| Other non-current liabilities | — | — | — | — | $0 |
| Common stock & paid-in capital | $34.0K | $30.0K | $28.0K | $25.0K | $24.0K |
| Retained earnings | -$552.4M | -$531.0M | -$503.8M | -$470.9M | -$423.8M |
| Accumulated other comprehensive income (loss) | — | — | $0 | -$1.1M | -$272.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$11.0M | -$17.9M | -$19.7M | -$36.9M | -$24.6M |
| Investing cash flow | -$332.0K | $9.0M | $23.0M | $23.8M | -$85.4M |
| Financing cash flow | $19.6M | $4.3M | $8.1M | $490.0K | $102.5M |
| Free cash flow | -$11.3M | -$18.3M | -$19.9M | -$37.5M | -$25.0M |
| Capital expenditures | $332.0K | $306.0K | $173.0K | $603.0K | $384.0K |
| Share-based compensation | $11.1M | $10.3M | $9.6M | $8.3M | $4.3M |
| Change in accounts receivable | $1.8M | $536.0K | $4.8M | $391.0K | -$1.3M |
| Change in inventory | $3.7M | $2.4M | $1.7M | $2.1M | $1.2M |
| Change in accounts payable | -$730.0K | $671.0K | $240.0K | $647.0K | $479.0K |
| Share repurchases | $49.5M | $0 | — | — | — |
| Tax withholding on stock comp | $543.0K | $881.0K | $259.0K | $59.0K | $0 |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding NPCE as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-03-20 to 2026-09-24
Recent transactions
- Most recent: Morrell Martha (CHIEF MEDICAL OFFICER) — Tax withholding of 335 shares on 2026-09-24.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 2026-09-24 | 335 |
| Williams Patrick F. | Chief Financial Officer | Tax withholding | 2026-09-20 | 1,162 |
| Becker Joel | CHIEF EXECUTIVE OFFICER | Tax withholding | 2026-09-03 | 1,310 |
| Geiger Uri | Director | Grant / award | 2026-06-19 | 789 |
| Fischer Frank M | Director | Grant / award | 2026-06-19 | 1,467 |
| Kumar Rakhi | Director | Grant / award | 2026-06-19 | 989 |
| Huennekens R Scott | Director | Grant / award | 2026-06-05 | 2,890 |
| Ryan Renee | Director | Grant / award | 2026-06-05 | 2,890 |
| Andrade Lisa | Director | Grant / award | 2026-06-05 | 2,890 |
| LACOB JOSEPH | Director | Grant / award | 2026-03-20 | 865 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-24 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 335 | $13.97 |
| 2026-09-20 | Williams Patrick F. | Chief Financial Officer | Tax withholding | 1,162 | $14.28 |
| 2026-09-03 | Becker Joel | CHIEF EXECUTIVE OFFICER | Tax withholding | 1,310 | $14.75 |
| 2026-08-27 | Becker Joel | CHIEF EXECUTIVE OFFICER | Tax withholding | 1,126 | $14.13 |
| 2026-08-27 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 358 | $14.13 |
| 2026-06-24 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 335 | $16.22 |
| 2026-06-19 | Geiger Uri | Director | Grant / award | 789 | $15.63 |
| 2026-06-19 | Fischer Frank M | Director | Grant / award | 1,467 | $15.63 |
| 2026-06-19 | Kumar Rakhi | Director | Grant / award | 989 | $15.63 |
| 2026-06-05 | Huennekens R Scott | Director | Grant / award | 2,890 | $0.00 |
| 2026-06-05 | Fischer Frank M | Director | Grant / award | 2,890 | $0.00 |
| 2026-06-05 | Geiger Uri | Director | Grant / award | 2,890 | $0.00 |
| 2026-06-05 | Kumar Rakhi | Director | Grant / award | 2,890 | $0.00 |
| 2026-06-05 | Ryan Renee | Director | Grant / award | 2,890 | $0.00 |
| 2026-06-05 | Andrade Lisa | Director | Grant / award | 2,890 | $0.00 |
| 2026-06-03 | Becker Joel | CHIEF EXECUTIVE OFFICER | Tax withholding | 1,255 | $15.88 |
| 2026-05-27 | Becker Joel | CHIEF EXECUTIVE OFFICER | Tax withholding | 1,126 | $17.06 |
| 2026-05-27 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 358 | $17.06 |
| 2026-05-15 | Williams Patrick F. | Chief Financial Officer | Grant / award | 16,820 | $0.00 |
| 2026-05-15 | Morrell Martha | CHIEF MEDICAL OFFICER | Grant / award | 5,460 | $0.00 |
| 2026-05-15 | Becker Joel | CHIEF EXECUTIVE OFFICER | Grant / award | 45,880 | $0.00 |
| 2026-03-24 | Morrell Martha | CHIEF MEDICAL OFFICER | Tax withholding | 1,341 | $13.27 |
| 2026-03-20 | Geiger Uri | Director | Grant / award | 913 | $13.00 |
| 2026-03-20 | LACOB JOSEPH | Director | Grant / award | 865 | $13.00 |
| 2026-03-20 | Kumar Rakhi | Director | Grant / award | 1,153 | $13.00 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:52 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-25 | 4 | 2026-09-24 | View on SEC.gov → |
| 2026-09-21 | 4 | 2026-09-20 | View on SEC.gov → |
| 2026-09-04 | 4 | 2026-09-03 | View on SEC.gov → |
| 2026-08-28 | 4 | 2026-08-27 | View on SEC.gov → |
| 2026-08-28 | 4 | 2026-08-27 | View on SEC.gov → |
| 2026-08-11 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-07-28 | 8-K | 2026-07-28 | View on SEC.gov → |
| 2026-06-25 | 4 | 2026-06-24 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-19 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-19 | View on SEC.gov → |
| 2026-06-22 | 4 | 2026-06-19 | View on SEC.gov → |
Recent news
Headlines about NPCE (Neuropace, Inc.). Links open the publisher — we don’t host full articles.
-
NeuroPace, Inc. (NPCE) - What Are Brokerages Saying About This Stock?
MarketBeat · 2026-10-18 -
Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?
Yahoo Finance · 2026-09-10 -
Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now
Yahoo Finance · 2026-09-04 -
NeuroPace to Participate in 2026 Cantor Global Healthcare Conference
Yahoo Finance · 2026-09-01 -
NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference
Yahoo Finance · 2026-08-31 -
NeuroPace Inc (NPCE) (Q2 2026) Earnings Call Highlights: Strong RNS Growth and AI Launch Offset ...
Yahoo Finance · 2026-08-19 -
NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth
Yahoo Finance · 2026-08-17 -
NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?
Yahoo Finance · 2026-08-17
No headlines in this category right now — try “All”.